| Literature DB >> 30683054 |
Mohammed Akeel1, Atef Shehata2,3, Ahmed Elhafey4,5, Erwa Elmakki6, Thanaa Aboshouk7, Hussein Ageely6, Mohammed Mahfouz8.
Abstract
BACKGROUND: The aim of this study was to identify the common H. pylori virulence genes among dyspeptic Southwestern Saudi patients and their association with clinical outcomes and histopathological findings to help practitioners and researchers in the region for better management of infections caused by such bacteria.Entities:
Keywords: Gastric ulcer; Gastritis; Genotype; H. pylori; PCR; Virulence genes
Mesh:
Substances:
Year: 2019 PMID: 30683054 PMCID: PMC6346553 DOI: 10.1186/s12876-019-0934-z
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Primers used for genotyping of H. pylori by detection of cagA, vacA and iceA genes
| Gene | Primer name | Primer sequence (5′ → 3′) a | PCR product size | Reference |
|---|---|---|---|---|
|
| cagA-F | GATAACAGGCAAGCTTTTGAGG | 349 | [ |
| cagA-R | CTGCAAAAGATTGTTTGGCAGA | [ | ||
| s1a | S1a-F | TCTYGCTTTAGTAGGAGC | 212 | [ |
| VA1-R | CTGCTTGAATGCGCCAAAC | [ | ||
| s1b | SS3-R | AGCGCCATACCGCAAGAG | 187 | [ |
| VA1-R | CTGCTTGAATGCGCCAAAC | [ | ||
| s1c | S1c-F | CTYGCTTTAGTRGGGYTA | 213 | [ |
| VA1-R | CTGCTTGAATGCGCCAAAC | [ | ||
| s2 | SS2-F | GCTAACACGCCAAATGATCC | 199 | [ |
| VA1-R | CTGCTTGAATGCGCCAAAC | [ | ||
| m1 | VA3-F | GGTCAAAATGCGGTCATGG | 290 | [ |
| VA3-R | CCATTGGTACCTGTAGAAAC | [ | ||
| m2 | VA4-F | GGAGCCCCAGGAAACATTG | 352 | [ |
| VA4-R | CATAACTAGCGCCTTGCAC | [ | ||
| iceA1-F | GTGTTTTTAACCAAAGTATC | 247 | [ | |
| iceA1-R | CTATAGCCASTYTCTTTGCA | [ | ||
| iceA2-F | GTTGGGTATATCACAATTTAT | 229/334 | [ | |
| iceA2-R | TTRCCCTATTTTCTAGTAGGT | [ | ||
| Luni1 | ACATTTTGGCTAAATAAACGCTG | 550 | [ | |
| R5280 | GGTTGCACGCATTTTCCCTTAATC | [ |
aY is C or T, R is A or G and S is C or G
Fig. 1Agarose gel electrophoresis of the PCR-based genotyping amplified products of (a) cagA gene (349 bp). Lanes; M; 100 bp DNA ladder (Solis Biodyne). Lanes 1, 2, 3, 5, 7, 9, 11, and 15 are cagA positive while remaining lanes are negative for this gene. b cag empty site (550 bp). Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 1, 2, 4, 5, 7, 8 are cagA empty site positive while the remaining lanes are negative for this site. c iceA1 gene (247 bp). Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 1, 2, 3, 4, 5, 7, 8, 9, 11, 13, 14 and 15 are iceA1 positive while remaining lanes are negative for this gene. Note that PCR bands in lanes 4 and 11 are faint. d iceA2 gene (229 or 334 bp). Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 1, 4, 6, 10, 11, and 12 are iceA2 positive while lanes 2, 3, 5, 7–9, 13–15 are negative for this gene. Note that PCR products in lanes 1, 6 and 12 are of 334 bp size, while lanes 4, 10 and 11 have 229 bp PCR products
Fig. 2Agarose gel electrophoresis of the PCR-based genotyping amplified products of vacA gene. a PCR products of vacA s1a gene (212 bp). Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 4, 5, 8, 9, and 10 are positive while lanes 1, 2, 3, 6, 7 and 9 are negative. b PCR products of vacA s1b gene (187 bp). Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 2, 5, 7, 8 and 9, while lanes 10 are positive while lanes 1, 3, 4 and 10 are negative. c products of vacA s2 gene (199 bp). a) Positive photo. b) Negative photo. Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 7 and 9 are positive while lanes 1, 2, 3, 4, 5, 6 and 8 are negative for this gene. d amplified products of vacA m1 gene (290 bp). a Positive photo. b Negative photo. Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 4 and 8 are positive while lanes 1, 2, 3, 5, 6, 7 and 9 are negative for this gene. e products of vacA m2 gene (352 bp). Lanes; M; 100 bp molecular DNA marker (Cleaver Scientific Ltd.). Lanes 1, 2, 3, 5, 6, 7 and 10 are positive while lanes 4, 8 and 9 are negative for this gene
Distribution of H. pylori vacA gene alleles according to cagA and iceA status
|
|
| Totala | ||||||
|---|---|---|---|---|---|---|---|---|
| positive | negative | mixed | mixed | negative | ||||
| s1 am1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| 1.6% | 0.0% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% | 0.8% | |
| s1bm1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 1.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.7% | 0.8% | |
| s1 am2 | 1 | 2 | 0 | 1 | 0 | 1 | 1 | 3 |
| 1.6% | 3.2% | 0.0% | 1.9% | 0.0% | 20.0% | 3.7% | 2.3% | |
| s1bm2 | 7 | 4 | 0 | 5 | 3 | 0 | 3 | 11 |
| 11.1% | 6.5% | 0.0% | 9.3% | 7.1% | 0.0% | 11.1% | 8.6% | |
| s2 m2 | 1 | 18 | 0 | 9 | 7 | 0 | 3 | 19 |
| 1.6% | 29.0% | 0.0% | 16.7% | 16.7% | 0.0% | 11.1% | 14.8% | |
| s1a | 7 | 2 | 0 | 5 | 1 | 0 | 3 | 9 |
| 11.1% | 3.2% | 0.0% | 9.3% | 2.4% | 0.0% | 11.1% | 7.0% | |
| m2 | 3 | 18 | 0 | 7 | 10 | 1 | 3 | 21 |
| 4.8% | 29.0% | 0.0% | 13.0% | 23.8% | 20.0% | 11.1% | 16.4% | |
| s1b | 2 | 1 | 0 | 1 | 1 | 0 | 1 | 3 |
| 3.2% | 1.6% | 0.0% | 1.9% | 2.4% | 0.0% | 3.7% | 2.3% | |
| s1a1b | 17 | 4 | 0 | 11 | 3 | 0 | 7 | 21 |
| 27.0% | 6.5% | 0.0% | 20.4% | 7.1% | 0.0% | 25.9% | 16.4% | |
| s1as1bm1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| 1.6% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% | 0.0% | 0.8% | |
| s1as1bm2 | 20 | 8 | 2 | 10 | 12 | 3 | 5 | 30 |
| 31.7% | 12.9% | 66.7% | 18.5% | 28.6% | 60.0% | 18.5% | 23.4% | |
| Mixed | 1 | 3 | 1 | 2 | 3 | 0 | 0 | 5 |
| 1.6% | 4.8% | 33.3% | 3.7% | 7.1% | 0.0% | 0.0% | 3.9% | |
| s2 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 2 |
| 0.0% | 3.2% | 0.0% | 1.9% | 2.4% | 0.0% | 0.0% | 1.6% | |
| m1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| 1.6% | 0.0% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% | 0.8% | |
| Totalb | 63 | 62 | 3 | 54 | 42 | 5 | 27 | 128 |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
aTotal number of vacA alleles. b Total number of vacA alleles according to cagA or iceA status. cagA mixed genotypes contain both cagA and cagA empty sites amplified PCR products
Distribution of genotypes according to the patients’ gender and age
| Genotype/allele | Gender | Age groups | Total |
| |||||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | 13–29 | 30–49 | 50+ | |||||
| N(%) | N(%) | N(%) | N(%) | N(%) | |||||
|
| s1 am1 | 0 (0.0) | 1 (100.0) | 0.514 | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0.305 |
| s1bm1 | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | |||
| s1 am2 | 1 (33.3) | 2 (66.7) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 3 (100.0) | |||
| s1bm2 | 8 (72.7) | 3 (27.3) | 6 (54.5) | 3 (27.3) | 2 (18.2) | 11 (100.0) | |||
| s2 m2 | 10 (52.6) | 9 (47.4) | 7 (36.8) | 9 (47.4) | 3 (15.8) | 19 (100.0) | |||
| s1a | 4 (44.4) | 5 (55.6) | 4 (44.4) | 4 (44.4) | 1 (11.1) | 9 (100.0) | |||
| m2 | 7 (33.3) | 14 (66.7) | 13 (61.9) | 5 (23.8) | 3 (14.3) | 21 (100.0) | |||
| s1b | 2 (66.7) | 1 (33.3) | 1 (33.3) | 2 (66.7) | 0 (0.0) | 3 (100.0) | |||
| s1a1b | 13 (61.9) | 8 (38.1) | 3 (14.3) | 12 (57.1) | 6 (28.6) | 21 (100.0) | |||
| s1as1bm1 | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) | |||
| s1as1bm2 | 17 (56.7) | 13 (43.3) | 7 (23.3) | 12 (40.0) | 11 (36.7) | 30 (100.0) | |||
| mixed | 1 (20.0) | 4 (80.0) | 3 (60.0) | 2 (40.0) | 0 (0.0) | 5 (100.0) | |||
| s2 | 1 (50.0) | 1 (50.0) | 1 (50.0) | 1 (50.0) | 0 (0.0) | 2 (100.0) | |||
| m1 | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | |||
|
| +ve | 30 (47.6) | 33 (52.4) | 0.741 | 20 (31.7) | 27 (42.9) | 16 (25.4) | 63 (100.0) | 0.218 |
| -ve | 32 (51.6) | 30 (48.4) | 26 (41.9) | 24 (38.7) | 12 (19.4) | 62 (100.0) | |||
| mixed | 2 (66.7) | 1 (33.3) | 0 (0.0) | 3 (100.0) | 0 (0.0) | 3 (100.0) | |||
|
| 27 (50.0) | 27 (50.0) | 0.528 | 16 (29.6) | 28 (51.9) | 10 (18.5) | 54 (100.0) | 0.571 | |
| 19 (45.2) | 23 (54.8) | 18 (42.9) | 15 (35.7) | 9 (21.4) | 42 (100.0) | ||||
| mixed | 4 (80.0) | 1 (20.0) | 2 (40.0) | 1 (20.0) | 2 (40.0) | 5 (100.0) | |||
| negative | 14 (51.9) | 13 (48.1) | 10 (37.0) | 10 (37.0) | 7 (26.0) | 27 (100.0) | |||
| Total | 64 (50) | 64 (50) | 46 (35.9) | 54 (42.2) | 28 (21.9) | 128 (100.0) | |||
Distribution of H. pylori cagA and iceA genotypes according to endoscopic findings and histopathological changes
| Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| positive | negative | mixed | mixed | negative | ||||||
| Endoscopic findings | ||||||||||
| Normal | 9 (45.0) | 11 (55.0) | 0 (0.0) | 0.480 | 4 (20.0) | 6 (30.0) | 0 (0.0) | 10 (50.0) | 20 (100.0) | 0.026 |
| Gastritis | 44 (48.4) | 44 (48.4) | 3 (3.3) | 42 (46.2) | 31 (34.1) | 4 (4.4) | 14 (15.4) | 91 (100.0) | ||
| Gastric ulcer | 4 (40.0) | 6 (60.0) | 0 (0.0) | 6 (60.0) | 3 (30.0) | 1 (10.0) | 0 (0.0) | 10 (100.0) | ||
| Duodenal ulcer | 6 (85.7) | 1 (14.3) | 0 (0.0) | 2 (28.6) | 2 (28.6) | 0 (0.0) | 3 (42.9) | 7 (100.0) | ||
| Histopathological changes | ||||||||||
| Mild chronic gastritis | 3 (60.0) | 2 (40.0) | 0 (0.0) | 0.724 | 2 (40.0) | 3 (60.0) | 0 (0.0) | 0 (0.0) | 5 (100.0) | 0 .479 |
| Moderate chronic gastritis | 11 (44.0) | 14 (56.0) | 0 (0.0) | 13 (52.0) | 6 (24.0) | 2 (8.0) | 4 (16.0) | 25 (100.0) | ||
| Severe gastritis | 2 (100.0) | 0 (0.0) | 0 (0.0) | 2 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (100.0) | ||
| Chromic active gastritis | 47 (49.0) | 46 (47.9) | 3 (3.1) | 37 (38.5) | 33 (34.4) | 3 (3.1) | 23 (24.0) | 96 (100.0) | ||
| Total | 63 (49.2) | 62 (48.4) | 3 (2.3) | 54 (42.2) | 42 (32.8) | 5 (3.9) | 27 (21.1) | 128 (100.0) | ||
Fig. 3The relationship of vacA with: a clinical outcomes (as detected by endoscopic findings) and b histopathological changes